Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

Core Viewpoint - Cognition Therapeutics is advancing the development of zervimesine for treating dementia with Lewy bodies (DLB) psychosis, which affects up to 75% of DLB patients, following positive feedback from the FDA [1][2][3] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for age-related neurodegenerative disorders [8] - The company has completed Phase 2 studies of zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies supported by significant grants from the National Institute on Aging [8] Drug Development - Zervimesine (CT1812) is an investigational oral medication aimed at treating CNS diseases, including Alzheimer's and DLB, by interrupting the toxic effects of Aβ and ɑ-synuclein [6][7] - The Phase 2 SHIMMER study demonstrated zervimesine's positive impact on neuropsychiatric symptoms, showing an 86% slowing of decline on the neuropsychiatric inventory compared to placebo [5] Regulatory Strategy - The company plans to pursue a registrational path for zervimesine based on the strength of Phase 2 data and FDA meeting minutes, aiming to expedite its market entry [2][3] - Cognition expects to meet with the FDA Division of Psychiatry to discuss the DLB psychosis program by mid-2026 [2] Patient Impact - DLB psychosis significantly burdens patients and caregivers, leading to higher healthcare costs and earlier institutionalization, with no approved medications currently available for this condition [4] - Zervimesine has shown a favorable impact on cognitive fluctuations, memory, movement, and daily living activities without impairing motor skills, addressing a critical need for DLB patients [3]